Skin care active substance and skin care product

Abstract

Provided are a skin care active substance and a skin care product. The skin care active substance comprises, in part by weight: 0.1-15 parts of a humectant and 0.05-2 parts of a soothing / antiallergic agent. The humectant comprises at least two of ceramide NP, hydrolyzed sodium hyaluronate, and sodium hyaluronate. The soothing / antiallergic agent comprises a paeonia root extract. By designing the above ingredients and the proportion thereof, the formed synergistic active substance can achieve moisturizing and soothing effects mildly and efficiently, protect the skin barrier effectively, and keep the health of the skin with good safety.

Description

Skin care actives, skin care products

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority based on Chinese patent application 202410108542.4 filed on January 25, 2024, and all of its contents are incorporated herein by reference. Technical Field

[0003] The present application relates to the technical field of skin care, and in particular to skin care active ingredients and skin care products. Background Art

[0004] Skin is the body's first line of defense against external aggressors, helping to protect the body from harmful substances such as bacteria. Healthy, hydrated skin helps ensure that it constantly renews itself to maintain its protective barrier function.

[0005] In today's society, people not only have to face the stimulation of sunlight ultraviolet rays, air pollution, and electronic products, but also have to face various pressures brought by life and work, which lead to sub-health of the skin barrier or even damage to the barrier. Most people's skin suffers from problems such as lack of moisture, oil-water imbalance, allergies and redness.

[0006] Summary of the Invention

[0007] The present application provides a skin care active ingredient and skin care product that has moisturizing and soothing effects, effectively protects the skin barrier, and maintains skin health.

[0008] In order to solve the above technical problems, the first aspect of the present application provides a skin care active ingredient, which includes 0.1-15 parts by weight of a moisturizer and 0.05-2 parts by weight of a soothing and anti-allergic agent in a weight ratio; wherein the moisturizer includes at least two of ceramide NP, hydrolyzed sodium hyaluronate, and sodium hyaluronate; and the soothing and anti-allergic agent includes peony root extract.

[0009] In one embodiment, the skin care active comprises, by weight, 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate; or

[0010] The skin care active ingredients include, by weight, 0.5-5 parts by weight of ceramide NP and 0.1-10 parts by weight of hydrolyzed sodium hyaluronate; or

[0011] The skin care active ingredients include, by weight, 0.5-5 parts by weight of ceramide NP and 0.1-10 parts by weight of sodium hyaluronate; or

[0012] The skin care active ingredients include, by weight, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate.

[0013] In one embodiment, the skin care active further comprises 0.01-25 parts by weight of a moisturizing and repairing agent, wherein the moisturizing and repairing agent comprises at least one of acetylglucosamine, α-hydroxy acid, hydroxyethylpiperazine ethane sulfonic acid, phytic acid, and hexanoyl dipeptide-3 norleucine acetate.

[0014] In one embodiment, the skin care active ingredients include, by weight, at least one of: 0.01-5 parts by weight of acetylglucosamine, 0.01-5 parts by weight of α-hydroxy acid, 0.01-5 parts by weight of hydroxyethylpiperazineethanesulfonic acid, 0.01-5 parts by weight of phytic acid, and 0.01-5 parts by weight of hexanoyl dipeptide-3 norleucine acetate.

[0015] In one embodiment, the skin care active is composed of the following components in the following weight ratios: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, 0.05-2 parts by weight of peony root extract, and 0.01-5 parts by weight of acetyl glucosamine; or,

[0016] The skin care active ingredient is composed of the following components in the following weight ratios: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, and 0.05-2 parts by weight of peony root extract; or

[0017] The skin care active ingredient is composed of the following components in the following weight ratios: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate, and 0.05-2 parts by weight of peony root extract; or

[0018] The skin care active ingredient is composed of the following components in the following weight ratio: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of sodium hyaluronate, and 0.05-2 parts by weight of peony root extract; or,

[0019] The skin care active ingredient is composed of the following components in the following weight ratios: 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, 0.05-2 parts by weight of peony root extract, and 0.01-5 parts by weight of acetyl glucosamine.

[0020] In one embodiment, in the 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, the weight ratio of the hydrolyzed sodium hyaluronate to the sodium hyaluronate is (2.5-4):(1.5-3).

[0021] In order to solve the above technical problems, the second aspect of the present application provides a skin care product, comprising any of the skin care active ingredients described above.

[0022] In one embodiment, the skin care product comprises 0.15-42 parts by weight of the skin care active ingredient and 7.5-14 parts by weight of the base material.

[0023] In one embodiment, the skin care product consists of the skin care active, the base and deionized water.

[0024] In one embodiment, the base material is composed of the following components in the following weight ratios: 3-5 parts by weight of glycerin, 2-3 parts by weight of polydimethylsiloxane, 1-3 parts by weight of squalane, 0.5-1 parts by weight of acrylic acid or acrylate or C10-30 alkyl acrylate crosspolymer, and 1-2 parts by weight of polysorbate 60.

[0025] In one embodiment, the dosage form of the skin care product includes any one of an aqueous solution, an emulsion, a cream, an essence lotion, a facial mask, and a spray.

[0026] The beneficial effects of this application are as follows: Different from the prior art, this application discloses a skin care active ingredient and a skin care product; the skin care active ingredient comprises, by weight, 0.1-15 parts by weight of a moisturizer and 0.05-2 parts by weight of a soothing and anti-allergic agent; wherein the moisturizer comprises at least two of ceramide NP, hydrolyzed sodium hyaluronate, and sodium hyaluronate, and the soothing and anti-allergic agent comprises peony root extract. By designing the above ingredients and their proportions, the synergistically formed active ingredient can gently and efficiently produce moisturizing and soothing effects, effectively protect the skin barrier, maintain skin health, and is highly safe.

[0027] The above description is only an overview of the technical solution of the present application. In order to more clearly understand the technical means of the present application, it can be implemented in accordance with the contents of the specification. In order to make the above and other purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are listed below. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without any creative work.

[0029] FIG1 is a comparison chart of cell proliferation activity test results;

[0030] FIG2 is a comparison chart of HaCaT cell proliferation activity test results;

[0031] FIG3 is a comparison chart of HSF cell proliferation activity test results;

[0032] Figure 4 is a comparison of cell scratches;

[0033] Figure 5 is a comparison chart of cell scratch test data;

[0034] Figure 6 is a comparison chart of ROS content detection;

[0035] Figure 7 is a comparison chart of ROS content detection data;

[0036] Figure 8 is a comparison of mitochondrial membrane potential;

[0037] Figure 9 is a comparison chart of mitochondrial membrane potential test data;

[0038] Figure 10 is a comparison chart of the TNF-ɑ content test results of each group;

[0039] Figure 11 is a comparison chart of the test results of PGE-2 content in each group;

[0040] Figure 12 is a comparison of the epidermal thickness results of each group;

[0041] Figure 13 is a diagram of the histological observation results of each group;

[0042] FIG14 is a graph showing the mean fluorescence intensity of FLG in each group. DETAILED DESCRIPTION

[0043] In order to make the purpose, technical solution and effect of this application clearer and more specific, the following embodiments of the technical solution of this application will be described in detail with reference to the accompanying drawings. The following embodiments are only used to more clearly illustrate the technical solution of this application and are therefore only examples and are not intended to limit the scope of protection of this application.

[0044] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application belongs; the terms used herein are only for the purpose of describing specific embodiments and are not intended to limit this application; the terms "including" and "having" and any variations thereof in the specification and claims of this application and the above-mentioned figure descriptions are intended to cover non-exclusive inclusions.

[0045] In the description of the embodiments of the present application, the technical terms "first" and "second" are used only to distinguish different objects and should not be understood as indicating or implying relative importance or implicitly indicating the quantity, specific order, or primary and secondary relationship of the indicated technical features. In the description of the embodiments of the present application, the term "multiple" refers to more than two (including two), similarly, "multiple groups" refers to more than two (including two), and "multiple pieces" refers to more than two (including two), unless otherwise clearly and specifically defined.

[0046] References herein to "embodiments" mean that a particular feature, structure, or characteristic described in connection with the embodiments may be included in at least one embodiment of the present application. The appearance of this phrase in various places in the specification does not necessarily refer to the same embodiment, nor does it constitute an independent or alternative embodiment that is mutually exclusive of other embodiments. It is understood, both explicitly and implicitly, by those skilled in the art that the embodiments described herein may be combined with other embodiments.

[0047] In the description of the embodiments of this application, the term "and / or" is simply a description of the association relationship between associated objects, indicating that three relationships can exist. For example, A and / or B can represent the following three situations: A exists alone, A and B exist simultaneously, and B exists alone. In addition, the character " / " in this document generally indicates that the associated objects are in an "or" relationship.

[0048] Amounts, ratios, and other numerical values ​​are presented herein in a range format. It should be understood that such range format is used for convenience and brevity and should be interpreted flexibly to include not only the values ​​explicitly specified as range limits, but also all individual values ​​or sub-ranges encompassed within the range, as if each value and sub-range were explicitly specified.

[0049] If not otherwise specified, all steps of the present application may be performed sequentially, randomly, or in parallel, preferably sequentially. For example, the method includes steps (a) and (b), indicating that the method may include steps (a) and (b) performed sequentially, or may include steps (b) and (a) performed sequentially, or may include steps (a) and (b) performed simultaneously in parallel. For example, the method may further include step (c), indicating that step (c) may be added to the method in any order, for example, the method may include steps (a), (b), and (c), or may include steps (a), (c), and (b), or may include steps (c), (a), and (b), etc.

[0050] Skin is the body's first line of defense against external aggressors, helping to protect the body from harmful substances such as bacteria. Healthy, hydrated skin helps ensure that it constantly renews itself to maintain its protective barrier function.

[0051] In today's society, people not only have to face the stimulation of sunlight ultraviolet rays, air pollution, and electronic products, but also have to face various pressures brought by life and work. People are in all kinds of adverse environments. Due to anxiety, inadequate sun protection, excessive skin care and other unhealthy lifestyles, the skin barrier becomes sub-healthy or even damaged, and the skin suffers from problems such as lack of moisture, oil-water imbalance, allergic redness, dryness, itching, stinging, redness and swelling.

[0052] Most of the products currently on the market that claim to have moisturizing and soothing effects mainly work by adding various moisturizing and anti-allergic ingredients to hydrate and block inflammation. Although these products can temporarily eliminate discomfort such as itching when used, their mechanism is only to relieve symptoms by inhibiting the release of inflammatory factors. The pathway of action is relatively simple and cannot fundamentally solve the problem of damaged skin barrier.

[0053] Dry and sensitive skin isn't a static state; it's a vicious cycle that, without intervention, can continue to worsen. The key focus at each stage of the sensitivity cycle should be on the damaged stratum corneum barrier. Therefore, truly disrupting the dry and sensitive skin cycle requires not only treating the symptoms but also repairing and strengthening the stratum corneum barrier function.

[0054] Based on this, the present application provides a skin care active ingredient and skin care product that can gently and efficiently produce moisturizing and soothing effects, effectively protect the skin barrier, maintain skin health, and has high safety.

[0055] The present invention provides a skin care active ingredient, comprising, by weight, 0.1-15 parts by weight of a moisturizing agent and 0.05-2 parts by weight of a soothing and anti-allergic agent; wherein the moisturizing agent comprises at least two of ceramide NP, hydrolyzed sodium hyaluronate, and sodium hyaluronate; and the soothing and anti-allergic agent comprises a peony root extract.

[0056] Ceramide NP is the primary building block of the skin barrier's brick wall structure, stimulating the synthesis of endogenous sebum components to moisturize and repair dry, aging skin. Both hydrolyzed sodium hyaluronate and sodium hyaluronate achieve moisturizing effects by strengthening the skin barrier and locking in moisture. The combination of hydrolyzed sodium hyaluronate and sodium hyaluronate, which contain hyaluronic acid of varying molecular weights, covers the skin from the surface to the deeper layers, strengthening the skin's barrier function and locking in moisture for a moisturizing effect. Paeonia lactiflora root extract optimizes cellular energy efficiency through mitochondrial autophagy, combating skin aging.

[0057] By designing skin care active ingredients including ceramide NP, hydrolyzed sodium hyaluronate, at least two of sodium hyaluronate and peony root extract, they work together to achieve efficient and gentle moisturizing and soothing effects, improve skin condition and maintain skin health.

[0058] In addition, the weight ratio of moisturizers and soothing anti-allergic agents in the skin care active ingredients is designed as above, so that the skin care active ingredients can act on the skin to moisturize and soothe, and the effect is long-lasting, while not causing any burden on the skin. It is highly safe, gently and efficiently improves the skin condition, effectively protects the skin barrier, and maintains the health of the skin.

[0059] It's important to note that healthy skin refers to skin that is smooth, soft, hydrated, even, firm, elastic, and flawless, based on the normal functioning of its physiological functions. Health is the foundation of beauty, and only healthy skin can achieve beauty. By empowering the skin with "balance, resilience, and self-healing abilities," we can gently and effectively maintain healthy skin.

[0060] Balance: The skin's surface and underlying layers, the stratum corneum and basal layer, each tightly bound together, enable the skin to maintain moisture and prevent water loss. The skin's ability to absorb and retain water, as well as the skin cells' ability to absorb and utilize oxygen, influence the skin's water balance and moisturizing capacity, as well as its metabolism and health, including its ability to heal itself.

[0061] Self-healing ability: The skin's ability to repair itself from damage, trauma, cell aging, etc., as well as the skin cells' ability to absorb and metabolize nutrients, affect the skin's metabolism and repair ability.

[0062] Resistance: The skin's ability to resist external environmental factors, including sunlight, pollutants, ultraviolet rays, bacteria, etc., as well as the skin cells' ability to identify and resist external pathogens and viruses, affect the health and appearance of the skin.

[0063] In this application, ceramide NP corresponds to "resistance," hydrolyzed sodium hyaluronate and sodium hyaluronate correspond to "balance," and peony root extract corresponds to "self-healing power." By designing skincare actives consisting of at least two of ceramide NP, hydrolyzed sodium hyaluronate, and sodium hyaluronate, along with peony root extract, this skincare active simultaneously incorporates "self-healing power," "resistance," and "balance," fundamentally improving skin and gently and efficiently maintaining healthy skin.

[0064] From another perspective, based on the framework of "balance, resistance, and self-healing power", the use of a combination of active ingredients that are "human homologous and plant-derived" can gently and efficiently achieve moisturizing and soothing effects, promoting the skin to a healthy state. In this application, ceramide NP, hydrolyzed sodium hyaluronate, and sodium hyaluronate are ingredients that are human homologous, and peony root extract is an ingredient that is plant-derived. This application designs skin care active ingredients to include at least two of ceramide NP, hydrolyzed sodium hyaluronate, and sodium hyaluronate, as well as peony root extract, so that the skin care active ingredients have both human homologous ingredients and plant-derived ingredients, achieving moisturizing and soothing effects efficiently and gently.

[0065] In one embodiment, the skin care active comprises 0.5-5 parts by weight of ceramide, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate. It will be appreciated that when the moisturizing agent for the skin care active comprises ceramide NP, hydrolyzed sodium hyaluronate and sodium hyaluronate, the skin care active comprises 0.5-5 parts by weight of ceramide, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate. Wherein, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate refer to the total weight of hydrolyzed sodium hyaluronate and sodium hyaluronate in the skin care active is 0.1-10 parts by weight. In the 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, the weight ratio of hydrolyzed sodium hyaluronate to sodium hyaluronate is (2.5-4):(1.5-3). Exemplarily, in 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, sodium hyaluronate includes sodium hyaluronate with a molecular weight of 220 WDa, sodium hyaluronate with a molecular weight of 138 WDa, and sodium hyaluronate with a molecular weight of 36 WDa, and hydrolyzed sodium hyaluronate includes hydrolyzed sodium hyaluronate with a molecular weight of 3.9 WDa and hydrolyzed sodium hyaluronate with a molecular weight of 7-8 KDa. 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate have hyaluronic acid of various molecular weights, covering the skin surface to the deep layers of the skin, strengthening the skin barrier function, locking in moisture, and achieving a moisturizing effect. The 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate in the following content are the same as this and will not be repeated here. For example, in 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, the weight ratio of hydrolyzed sodium hyaluronate to sodium hyaluronate can be 3.5:2.5, 3:2.5, 3:2, 3.5:2, etc.

[0066] In one embodiment, the skin care active comprises 0.5-5 parts by weight of ceramide NPs and 0.1-10 parts by weight of hydrolyzed sodium hyaluronate. It will be appreciated that when the moisturizing agent for the skin care active comprises ceramide NPs and hydrolyzed sodium hyaluronate, the skin care active comprises 0.5-5 parts by weight of ceramide and 0.1-10 parts by weight of hydrolyzed sodium hyaluronate.

[0067] In one embodiment, the skin care active comprises 0.5-5 parts by weight of ceramide NPs and 0.1-10 parts by weight of sodium hyaluronate. It will be appreciated that when the moisturizing agent for the skin care active comprises ceramide NPs and sodium hyaluronate, the skin care active comprises 0.5-5 parts by weight of ceramide and 0.1-10 parts by weight of sodium hyaluronate.

[0068] In one embodiment, the skin care active comprises 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate. It will be appreciated that when the moisturizing agent for the skin care active comprises hydrolyzed sodium hyaluronate and sodium hyaluronate, the skin care active comprises 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate.

[0069] In one embodiment, when the soothing and anti-allergic agent is composed of a peony root extract, the skin care active comprises 0.05-2 parts by weight of the peony root extract.

[0070] In one embodiment, the skin care active further comprises 0.01-25 parts by weight of a moisturizing and repairing agent, comprising at least one of acetylglucosamine, α-hydroxy acid, hydroxyethylpiperazineethane sulfonic acid, phytic acid, and hexanoyl dipeptide-3 norleucine acetate. The moisturizing and repairing agent has moisturizing and repairing properties; for example, acetylglucosamine has moisture-locking, moisturizing, brightening, and repairing properties. Including a moisturizing and repairing agent in the skin care active further enhances the moisturizing effect while also imparting a repairing effect to the skin care active. By adjusting the weight ratio of the moisturizing and repairing agent as described above, the skin care active achieves moisturizing and repairing properties without burdening the skin, resulting in increased safety. Optionally, the skin care active comprises, by weight, at least one of: 0.01-5 parts by weight of acetylglucosamine, 0.01-5 parts by weight of α-hydroxy acid, 0.01-5 parts by weight of hydroxyethylpiperazineethanesulfonic acid, 0.01-5 parts by weight of phytic acid, and 0.01-5 parts by weight of hexanoyl dipeptide-3 norleucine acetate. Optionally, the skin care active comprises a moisturizing and repairing agent. When the moisturizing and repairing agent comprises acetylglucosamine, the skin care active comprises 0.01-5 parts by weight of acetylglucosamine.

[0071] Additionally, acetyl glucosamine, alpha-hydroxy acid, hydroxyethylpiperazine ethane sulfonic acid, phytic acid, and hexanoyl dipeptide-3 norleucine acetate correspond to the "self-healing power" of the skin, further fundamentally improving it and gently and effectively maintaining healthy skin. Acetyl glucosamine, alpha-hydroxy acid, hydroxyethylpiperazine ethane sulfonic acid, phytic acid, and hexanoyl dipeptide-3 norleucine acetate are human-derived ingredients, gently and effectively achieving moisturizing and repairing effects.

[0072] In one embodiment, the skin care active is composed of the following components in the following weight ratio: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, 0.05-2 parts by weight of peony root extract, and 0.01-5 parts by weight of acetyl glucosamine.

[0073] In one embodiment, the skin care active is composed of the following components in the following weight ratios: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and hyaluronic acid, and 0.05-2 parts by weight of peony root extract.

[0074] In one embodiment, the skin care active ingredient is composed of the following components in the following weight ratio: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate, and 0.05-2 parts by weight of peony root extract.

[0075] In one embodiment, the skin care active is composed of the following components in the following weight ratios: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of sodium hyaluronate, 0.05-2 parts by weight of peony root extract

[0076] In one embodiment, the skin care active is composed of the following components in the following weight ratio: 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, 0.05-2 parts by weight of peony root extract, and 0.01-5 parts by weight of acetyl glucosamine.

[0077] It should be noted that when the skin care active includes 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, the total weight of hydrolyzed sodium hyaluronate and sodium hyaluronate in the skin care active can be 0.1 parts by weight, 0.5 parts by weight, 1 part by weight, 1.5 parts by weight, 2 parts by weight, 2.5 parts by weight, 3 parts by weight, 3.5 parts by weight, 4 parts by weight, 4.5 parts by weight, 5 parts by weight, 5.5 parts by weight, 6 parts by weight, 6.5 parts by weight, 7 parts by weight, 7.5 parts by weight, 8 parts by weight, 8.5 parts by weight, 9 parts by weight, 10 parts by weight, etc., or a range consisting of any two of the above values, for example, 0.1-5 parts by weight, 3-8 parts by weight, etc.

[0078] When the skin care active includes 0.1-10 parts by weight of hydrolyzed sodium hyaluronate, the weight of hydrolyzed sodium hyaluronate in the skin care active can be 0.1 parts by weight, 0.5 parts by weight, 1 part by weight, 1.5 parts by weight, 2 parts by weight, 2.5 parts by weight, 3 parts by weight, 3.5 parts by weight, 4 parts by weight, 4.5 parts by weight, 5 parts by weight, 5.5 parts by weight, 6 parts by weight, 6.5 parts by weight, 7 parts by weight, 7.5 parts by weight, 8 parts by weight, 8.5 parts by weight, 9 parts by weight, 10 parts by weight, etc., or a range consisting of any two of the above values, for example, 0.1-2 parts by weight, 1.5-6 parts by weight, etc.

[0079] When the skin care active includes 0.1-10 parts by weight of sodium hyaluronate, the weight of sodium hyaluronate in the skin care active can be 0.1 parts by weight, 0.5 parts by weight, 1 part by weight, 1.5 parts by weight, 2 parts by weight, 2.5 parts by weight, 3 parts by weight, 3.5 parts by weight, 4 parts by weight, 4.5 parts by weight, 5 parts by weight, 5.5 parts by weight, 6 parts by weight, 6.5 parts by weight, 7 parts by weight, 7.5 parts by weight, 8 parts by weight, 8.5 parts by weight, 9 parts by weight, 10 parts by weight, etc., or a range consisting of any two of the above values, for example, 0.5-5 parts by weight, 2-8 parts by weight, etc.

[0080] When the skin care active includes ceramide NPs, the weight amount of ceramide NPs in the skin care active can be 0.5 parts by weight, 1 part by weight, 1.5 parts by weight, 2 parts by weight, 2.5 parts by weight, 3 parts by weight, 3.5 parts by weight, 4 parts by weight, 4.5 parts by weight, 5 parts by weight, etc., or a range consisting of any two of the above values, such as 0.5-2 parts by weight, 1-4 parts by weight, etc.

[0081] When the skin care active includes peony root extract, the weight portion of peony root extract in the skin care active can be 0.05 weight part, 0.1 weight part, 0.4 weight part, 0.7 weight part, 1 weight part, 1.3 weight parts, 1.6 weight parts, 1.9 weight parts, 2 weight parts, etc., or a range consisting of any two of the above values, for example, 0.1-1 weight part, 0.4-1.6 weight parts, etc.

[0082] When the skin care active includes at least one of acetylglucosamine, α-hydroxy acid, hydroxyethylpiperazine ethane sulfonic acid, phytic acid, and hexanoyl dipeptide-3 norleucine acetate, the weight amounts of acetylglucosamine, α-hydroxy acid, hydroxyethylpiperazine ethane sulfonic acid, phytic acid, and hexanoyl dipeptide-3 norleucine acetate in the skin care active can be 0.01 parts by weight, 0.1 parts by weight, 0.5 parts by weight, 1 part by weight, 1.5 parts by weight, 2 parts by weight, 2.5 parts by weight, 3 parts by weight, 3.5 parts by weight, 4 parts by weight, 4.5 parts by weight, 5 parts by weight, etc., respectively, or a range consisting of any two of the above values, for example, 0.01-3 parts by weight, 0.5-4 parts by weight, etc.

[0083] The embodiments of the present application also provide a skin care product, which includes the skin care active ingredients introduced in the above embodiments and has at least the same advantages as the above skin care active ingredients.

[0084] In one embodiment, the skin care product comprises, by weight, 0.15-42 parts of the skin care active and 7.5-14 parts of the base. Alternatively, the skin care product comprises, by weight, 0.16-22 parts of the skin care active. The base typically includes a moisturizing ingredient. It should be noted that the composition and proportions of the skin care active are as described above and will not be further elaborated.

[0085] The combination of skin care active ingredients and base materials forms a skin care product that can gently and effectively produce moisturizing, soothing and repairing effects, effectively protecting the skin barrier and maintaining skin health.

[0086] In one embodiment, the skin care product comprises a skin care active ingredient, a base, and deionized water. Optionally, the amount of deionized water to be added is calculated from the total weight of the skin care product being 100 parts by weight minus the sum of the weight of the skin care active ingredient and the weight of the base.

[0087] In one embodiment, the dosage form of the skin care product includes any one of a water solution, an emulsion, a cream, an essence lotion, a facial mask, and a spray. The skin care active ingredient can achieve moisturizing, soothing, and repairing effects in any of these dosage forms. The dosage form is selected based on specific needs; the base ingredients are designed based on the desired dosage form.

[0088] In one embodiment, the base is composed of the following components in the following weight ratios: 3-5 parts by weight of glycerin, 2-3 parts by weight of polydimethylsiloxane, 1-3 parts by weight of squalane, 0.5-1 parts by weight of acrylic acid, acrylic acid esters, or C10-30 alkyl acrylate crosspolymer, and 1-2 parts by weight of polysorbate 60. This base is suitable for use in serum emulsion formulations, where polysorbate 60 provides an emulsifying effect and acrylic acid esters provide a thickening effect.

[0089] In one embodiment, the skin care product is composed of the following components in the following weight ratios: 0.5-5 parts by weight of ceramide NP, 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, 0.05-2 parts by weight of peony root extract, 0.01-5 parts by weight of acetylglucosamine, 3-5 parts by weight of glycerin, 2-3 parts by weight of polydimethylsiloxane, 1-3 parts by weight of squalane, 0.5-1 parts by weight of acrylic acid or acrylate or C10-30 alkyl acrylate crosspolymer, 1-2 parts by weight of polysorbate 60, and the remaining parts by weight being deionized water. The total weight of the skin care product is 100 parts. Among them, in the 0.1-10 parts by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate, the weight ratio of hydrolyzed sodium hyaluronate to sodium hyaluronate is (2.5-4): (1.5-3).

[0090] The skin care actives provided in this application have moisturizing, soothing, and repairing effects, and relevant experimental tests and studies have been conducted at the cellular level, biochemical reagent level, skin model level, and human body level. Below, a skin care product is composed of the following components in the following weight ratio: 1.5 parts by weight of ceramide NP, 1 part by weight of hydrolyzed sodium hyaluronate and sodium hyaluronate (wherein, hydrolyzed hyaluronic acid is 0.6 parts by weight and sodium hyaluronate is 0.4 parts by weight), 0.4 parts by weight of peony root extract, 0.1 parts by weight of acetylglucosamine, 5 parts by weight of glycerin, 2.4 parts by weight of polydimethylsiloxane, 2 parts by weight of squalane, 0.8 parts by weight of C10-30 alkyl acrylate crosspolymer, 1.3 parts by weight of polysorbate-60, and 85.5 parts by weight of deionized water as an example, and experimental tests at the cellular level, biochemical reagent level, skin model level, and human body level are conducted.

[0091] 1. Cell proliferation activity assay.

[0092] Experimental steps:

[0093] (1) Cells were seeded into 96-well plates, and 100 μL of culture medium containing 8 × 103 cells was added to each well. The plates were incubated at 37°C for 24 h until the cells adhered to the plate and entered the logarithmic growth phase.

[0094] (2) After 24 hours, the culture medium in step (1) was discarded, and 100 μL of the test solution of different concentrations was added to each well. Three parallel wells were set for each concentration, and the cells were incubated for 24 hours.

[0095] (3) Add 90 μL of fresh culture medium and 10 μL of CCK-8 solution (Cell Counting Kit-8 reagent) to the test solution added in step (2) and incubate for 1 to 4 hours.

[0096] (4) Measure the absorbance at 450 nm using an enzyme-labeled instrument.

[0097] Calculation method: Cell viability*(%)=[A(sample added)-A(blank) / [A(0 sample added)-A(blank)]×100;

[0098] Wherein, A(sample added) represents the absorbance of the wells containing cells, CCK-8 solution, and test solution;

[0099] A (blank) indicates the absorbance of wells with culture medium and CCK-8 solution but no cells;

[0100] A(0 loading) represents the absorbance of the wells containing cells and CCK-8 solution but no test solution;

[0101] Cell viability* indicates cell proliferation activity or cytotoxic activity.

[0102] It should be noted that when adding the culture medium containing CCK-8 to the cells in step (3), several blank wells without cells are added simultaneously to correct the values, which are referred to as A (blank). In step (2), several wells do not contain the test solution, but only the cell culture medium, which are referred to as A (0 addition).

[0103] Experimental results:

[0104] The experimental results are shown in Figures 1 to 3. Figure 1 is a comparison chart of cell proliferation activity test results, Figure 2 is a comparison chart of HaCaT cell proliferation activity test results, and Figure 3 is a comparison chart of HSF cell proliferation activity test results.

[0105] According to Figure 1, cell activity tests were conducted on cells using skin care active ingredients at concentrations of 10%, 5%, 1%, 0.1%, 0.05%, 0.001%, and 0, respectively. Excellent proliferation activity was expressed at concentrations of 0.05% and 0.1%, which increased by 15.99% and 8.79%, respectively, compared to the cell activity at a concentration of 0.

[0106] According to Figures 2 and 3, the skin care product provided in the present application can significantly promote cell proliferation and has a significant pro-proliferation effect: the proliferation activity of HaCaT cells increases by 18.7%; the proliferation activity of HSF cells increases by 90%.

[0107] 2. Cell scratch test.

[0108] Experimental steps:

[0109] (1) HaCaT cells were seeded into 12-well plates and incubated at 37°C for 24 h. The cells adhered to the plate and entered the logarithmic growth phase.

[0110] (2) After 24 hours, discard the culture medium and add 100 μL of 0.05% concentration test solution to each well. Set up three parallel wells and incubate for 24 hours.

[0111] (3) Use a 100 μl pipette tip to make three parallel slits in each well, wash with PBS to remove the cells, add serum-free culture medium, take a photo under a microscope at 0 h, and continue to culture in the incubator for 24 h.

[0112] (4) After 24 hours, take photos under a microscope.

[0113] (5) Calculate the cell migration rate after 24 hours.

[0114] Experimental results:

[0115] The experimental results are shown in Figures 4 and 5, Figure 4 is a cell scratch comparison diagram, and Figure 5 is a cell scratch test data comparison diagram. As shown in Figures 4 and 5, the skin care products provided in the examples of the present application can significantly promote cell migration rate and have a significant repair effect; compared with the cell migration rate of the blank control group of 46.5%, the cell migration rate of the skin care product composition provided in the examples of the present application is 92.1%, an increase of 45.6%. Among them, the blank control group is a number of wells in step (2) in which no test solution is added. It should be noted that in Figures 2 and 3, the positive control is the addition of EGF (growth factor, a substance with the effect of promoting migration).

[0116] 3. DPPH free radical scavenging experiment.

[0117] Experimental steps:

[0118] (1) Reagent preparation: Prepare a 150 μM DPPH (i.e., 150 μmol / L DPPH) solution in 80% ethanol.

[0119] (2) Sample addition: Add 20 μL of sample to each well, then add 180 μL of DPPH solution, and react at room temperature in the dark for 30 minutes.

[0120] (3) Detection: The absorbance at 517 nm was measured using an enzyme-labeled instrument, and the inhibition rate was calculated.

[0121] Calculation method: inhibition rate % = (1-A1 / A0) × 100%;

[0122] Wherein, A0 represents the absorbance value of the blank group at 517 nm; A1 represents the absorbance value of the sample group at 517 nm.

[0123] It should be noted that the sample is the skin care product of this application. The blank group refers to the wells without sample added.

[0124] Experimental results:

[0125] The experimental results are shown in Table 1 below. The skin care actives provided in the examples of the present application can significantly inhibit DPPH free radicals with a scavenging rate of 47.5%, and have significant antioxidant effects.

[0126] Table 1 DPPH test results of skin care actives

[0127] 4. ROS content detection experiment.

[0128] Experimental steps:

[0129] (1) Load the probe.

[0130] (a) Cell preparation: Cells were plated one day before the assay to ensure that the cell confluence reached 50-70% at the time of assay.

[0131] (b) Sample addition: After 24 hours, the culture medium was discarded and 100 μL of a 0.05% concentration of the test solution was added to each well. Three parallel wells were set up and incubated for 24 hours. The culture medium was a 9:1 mixture of DMEM and fetal bovine serum.

[0132] (c) Drug induction: Remove the cell culture medium, dilute H2O2 to a concentration of 2 mmol / L with serum-free medium, and incubate in a cell culture incubator at 37°C in the dark for 4 h.

[0133] (d) Probe preparation: Before probe loading, DCFH-DA was diluted 1:1000 in serum-free culture medium to a final concentration of 10 μM.

[0134] (e) Probe loading: Remove the induction drug by aspiration and add an appropriate volume of diluted DCFH-DA working solution, sufficient to cover the cells. For example, for a 6-well plate, this should be at least 1000 μL, and for a 96-well plate, this should be at least 100 μL. Incubate in a 37°C cell culture incubator in the dark for 30 min.

[0135] (f) Cell washing: Wash the cells 1 to 2 times with serum-free culture medium to fully remove DCFH-DA that has not entered the cells.

[0136] (2) Detection: In situ probe loading method: direct observation using a laser confocal microscope.

[0137] Experimental results:

[0138] The ROS content detection experiment is shown in Figures 6 and 7. Figure 6 is a comparison chart of ROS content detection, and Figure 7 is a comparison chart of ROS content detection data. According to Figures 6 and 7, the skin care composition provided in this application can significantly reduce the amount of ROS generated after UVB treatment, with a clearance rate of 99.6%, reflecting the strong antioxidant ability of the composition, which can effectively protect the skin barrier and reduce the invasion of external free radicals. It should be noted that the negative control group did not add samples and was not UVB irradiated; the model group did not add samples and was UVB irradiated; skin care products refer to those that were UVB irradiated while adding skin care active ingredients.

[0139] 5. Mitochondrial membrane potential detection experiment.

[0140] Experimental steps:

[0141] (1) Cell preparation: Cells were plated one day before the test to ensure that the cell confluence reached 50-70% at the time of the test.

[0142] (2) Sample addition: After 24 hours, the culture medium was discarded and 100 μL of 0.05% concentration of the test solution was added to each well. Three parallel wells were set up and incubated for 24 hours. The culture medium was prepared by mixing DMEM with fetal bovine serum in a ratio of 9:1.

[0143] (3) Aspirate the culture medium and wash the cells once with PBS or other appropriate solution if necessary according to the specific experiment.

[0144] (4) Drug induction: Remove the cell culture medium, dilute H2O2 to a concentration of 2 mmol / L with serum-free culture medium, and incubate in a cell culture incubator at 37°C in the dark for 4 hours.

[0145] (5) Aspirate the culture medium, wash the cells once with PBS, add 1 mL of JC-1 staining solution, and mix thoroughly. Incubate in a cell culture incubator at 37°C for 20 minutes. The JC-1 stock solution is 500X (that is, 500 times, the concentration of the staining solution is 1 times, that is, 1X, and the JC-1 staining solution is the 1X concentration after dilution).

[0146] (6) During the incubation period, prepare an appropriate amount of JC-1 staining buffer (1×) by adding 4 mL of distilled water per 1 mL of JC-1 staining buffer (5×) and place it in an ice bath.

[0147] (7) After incubation at 37°C, remove the supernatant and wash twice with JC-1 staining buffer (1×).

[0148] (8) Add 2 mL of cell culture medium containing serum and phenol red.

[0149] (9) Observe under a fluorescence microscope or laser confocal microscope.

[0150] Experimental results:

[0151] The experimental results are shown in Figures 8 and 9. Figure 8 is a comparison diagram of mitochondrial membrane potential, and Figure 9 is a comparison diagram of mitochondrial membrane potential test data. As shown in Figures 8 and 9, the skin care products provided in the examples of the present application can significantly reduce damage to mitochondria and have a significant mitochondrial protective effect; compared to the mitochondrial red fluorescence value of 0.63 in the blank control group, the mitochondrial red fluorescence value of the skin care product composition provided in the examples of the present application is 0.73, and the protection rate is increased by 10%. It should be noted that the blank control group did not add samples and did not undergo H2O2 induction; the model group did not add samples and underwent H2O2 induction; the skin care products refer to those that have undergone H2O2 induction while adding skin care active ingredients.

[0152] 6. Skin model: TNF-ɑ, PGE-2, tissue morphology test.

[0153] Experimental Materials:

[0154] (1) Detection kit: Episkin in vitro artificial skin model detection kit, batch number: 23ER060515S1.

[0155] (2) Culture conditions: 37°C, 5% CO2, relative humidity 95%.

[0156] (3) Culture medium: skin model maintenance culture medium (Lot: 23-MAIN-0512) and test culture medium (Lot: 23-ASSAY-0512).

[0157] (4) Tissue fixative: 4% neutral paraformaldehyde solution.

[0158] (5) Human TNF-α ELISA kit, Lot: H221109-103a.

[0159] (6) PGE-2 ELISA kit, Lot: 0674976.

[0160] (7) Sodium dodecyl sulfate (SDS): CAS: 151-21-3, LOT: WXBD6396V.

[0161] Experimental steps:

[0162] (1) Preparation of skin model: Add pre-warmed maintenance culture medium into a 12-well culture plate (2 mL / well), transfer the skin model to the plate containing the maintenance culture medium, and culture in an incubator overnight.

[0163] (2) Sample application: Take 10 μL of the test sample and evenly apply it to the surface of the epidermal model. The experimental groups and exposure conditions are shown in Table 2. Each experimental group has three parallels. After the specified exposure time, the sample is thoroughly rinsed with DPBS until no residue is left. Then, it is placed in fresh maintenance medium for further incubation or exposure to the test substance. It should be noted that TA in Table 5 represents sample.

[0164] Table 2 Grouping sample addition table

[0165] (3) Remove the epidermal tissue from the skin model using a punch and transfer it to a 2 mL EP centrifuge tube. Add 2 mL of neutral paraformaldehyde solution to each tube and fix it at room temperature for at least 24 h. After conventional embedding, sectioning, and HE staining, observe the morphology under a microscope.

[0166] (4) The culture medium of each well model was collected and stored at -80°C. The TNF-α content and PGE-2 content were determined using an ELISA kit.

[0167] Experimental results:

[0168] (1)TNF-ɑ.

[0169] The results of TNF-ɑ content are shown in Table 3 and Figure 10. Figure 10 is a comparison chart of the test results of TNF-ɑ content in each group.

[0170] Table 3 TNF-ɑ content results

[0171] In Table 3 and Figure 10, * indicates that the difference compared with the model group is statistically significant (P < 0.05); # indicates that the difference compared with the control group is statistically significant (P < 0.05). According to Table 3 and Figure 10, under the action of SDS damage, the TNF-α content of the model group was significantly increased compared with the control group (p < 0.05), indicating that the modeling was successful; compared with the model group, the TNF-α content of the positive group was significantly reduced, by 44.00% (p < 0.05). Compared with the model group, the TNF-α content of the sample group was significantly reduced, by 28.97% (p < 0.05), indicating that the skin care products of this application have a certain anti-irritation and soothing effect on the epidermal model after irritation and damage.

[0172] (2) PGE-2.

[0173] The results of PGE-2 content are shown in Table 4 and Figure 11. Figure 11 is a comparison chart of the test results of PGE-2 content in each group.

[0174] Table 4 PGE-2 content results

[0175] In Table 7 and Figure 4, * indicates that the difference is statistically significant compared with the model group (P < 0.05); # indicates that the difference is statistically significant compared with the control group (P < 0.05). According to Table 4 and Figure 11, under the action of SDS damage to the epidermal model, the PGE-2 content in the model group was significantly increased compared with the control group (p < 0.05), indicating that the modeling was successful; compared with the model group, the PGE-2 content in the positive group was significantly reduced, decreasing by 27.05% (p < 0.05). Compared with the model group, the PGE-2 content in the sample group was significantly reduced, decreasing by 29.78% (p < 0.05), indicating that the skin care products of this application have a certain anti-irritation and soothing effect on the epidermal model after irritation and damage.

[0176] (3) Tissue morphology and epidermal thickness.

[0177] The results of histological analysis are shown in Table 5 and Figures 12 and 13. Figure 12 is a comparison of the epidermal thickness results of each group. Figure 13 is a diagram of the histological observation results of each group (under a microscope at 400×).

[0178] Table 5 Histological analysis results

[0179] In Table 5 and Figure 12, * indicates that the difference is statistically significant compared with the model group (P < 0.05); # indicates that the difference is statistically significant compared with the control group (P < 0.05). According to Table 5 and Figures 12 and 13, the epidermal model is significantly thinner and the cell layer is reduced in the model group compared with the control group under the action of SDS damage, and the SDS modeling is effective (p < 0.05). After SDS damage, the sample (i.e., the skin care product of the present application) was applied. Compared with the model group, the epidermal thickness of the sample group was significantly improved, and it increased by 369.31μm (p < 0.05), indicating that the skin care product of the present application has a certain anti-irritation and soothing effect on the epidermal model after irritation and damage.

[0180] The results of tissue morphology test showed that compared with the control group, the epidermis of the model group epidermis model was thinner, the living cell layer was damaged, the number of living cell layers decreased, and vacuoles appeared, indicating that the SDS stimulation modeling conditions were effective. Compared with the model group, the four-layer structure of the positive group model had clear boundaries, the cells in the cell layer were compactly arranged, and the basal layer was intact, indicating that the positive control test was effective. The epidermal model structure of the sample control group was intact, indicating that the sample itself had no obvious stimulating effect on the epidermal model. Compared with the model group, the tissue morphology of the sample group model was significantly improved, the epidermal model structure was intact, the boundaries were clear, and the cells in the cell layer were compactly arranged, indicating that the skin care products of this application have a certain anti-irritation and soothing effect on the epidermal model after stimulation and damage.

[0181] 7. Skin model: FLG (filament aggregate protein) test.

[0182] Experimental groups:

[0183] Table 6 FLG test experiment grouping

[0184] Experimental reagents: Anti-Filaggrin antibody: Abcam-ab81468.

[0185] Experimental steps:

[0186] (1) Pre-incubation of the whole skin model.

[0187] (a) After receiving the model, first preheat the accompanying culture medium.

[0188] (b) Add preheated culture medium to the included blue deep-well plate at a volume of 8.5 mL per well. Remove the model from the test kit using tweezers, remove any remaining agarose gel culture medium, and immediately transfer it to the pre-filled blue deep-well plate. Ensure that each skin model fits snugly into the well, with the base membrane of each skin model in contact with the liquid surface, ensuring that no air bubbles are trapped between the model and the culture medium.

[0189] (c) Place the plate in an incubator at 37°C, 5% CO2 overnight until use.

[0190] (2) Raw material processing.

[0191] (a) Prepare a certain volume of culture medium containing the active substance according to the concentration.

[0192] (b) Remove the 6-well plate from the incubator, remove the culture medium from the bottom of the model using a pipette, and add 8.5 mL / well of fresh culture medium containing the active ingredient prepared in step (a). After the medium is replaced, ensure that the base membrane of each skin model is in contact with the liquid surface. Return the plate to the incubator and incubate at 37°C, 5% CO2 for 48 hours.

[0193] (3) Collection of skin model samples.

[0194] After the model incubation is complete (i.e., after step (2)), the model is carefully removed from the well plate with tweezers, the skin tissue is punched out with a punch, and the tissue is cut with a sharp blade. The tissue used for immunofluorescence experiments is fixed in OCT frozen section embedding medium. During the fixation process, the bubbles in the OCT gel must be removed. The tissue is then quickly placed in liquid nitrogen, labeled with groups, and stored at -80°C.

[0195] (4) Tissue immunofluorescence.

[0196] Experimental process:

[0197] Allow frozen sections to dry at room temperature for 15 minutes. Use an immunohistochemistry pen to circle the tissue to be stained and soak in PBS for 10 minutes to remove the OCT cryosection embedding medium. Block sections with PBS containing 10% serum at room temperature. Apply various concentrations of primary antibody to the sections and incubate overnight at 4°C. Rinse sections three times with PBS for 10 minutes each. Add various concentrations of secondary antibody and incubate at 37°C for 1-2 hours. Rinse sections three times with PBS for 10 minutes each. Finally, mount the sections and observe the results under a fluorescence microscope and photograph.

[0198] Experimental results:

[0199] The average fluorescence intensity of FLG is shown in Table 7 and Figure 14. Figure 14 is a graph showing the average fluorescence intensity of FLG in each group.

[0200] Table 7 FLG mean fluorescence intensity (Mean±SD)

[0201] As shown in Table 7 and Figure 14, after 48 hours of exposure to T-Skin™ (a skin model) at a concentration of 0.6 mg / mL, the skincare product of this application exhibited significant fluorescence intensity for FLG (filaggrin). The relative fluorescence intensity of FLG accounted for 193.30%, a 93.30% increase compared to the negative control group, demonstrating that the skincare product of this application exhibits significant moisturizing and repairing properties.

[0202] 8. Human body efficacy: test of stratum corneum water content.

[0203] (1) Inclusion criteria.

[0204] (a) Healthy male / female subjects, aged 20-45 years, 5 people;

[0205] (b) A well-cooperative subject who can remain in a constant temperature and humidity chamber for at least 20 minutes during the test;

[0206] (c) Be able to read and understand all the contents of the informed consent form and voluntarily sign the informed consent form;

[0207] (d) During the trial, the patient agrees not to use any cosmetics, drugs or health products that may affect the results.

[0208] (2)Exclusion criteria.

[0209] Patients with any of the following conditions must be excluded from this study.

[0210] (a) The test area has skin diseases that may affect the judgment of the test results;

[0211] (b) Those with highly allergic constitution;

[0212] (c) Women who are pregnant, breastfeeding or planning to become pregnant during the testing period;

[0213] (d) Those who are unable to cooperate with the experiment.

[0214] (3) Usage method and frequency.

[0215] Apply the sample to the corresponding marked area on the inner arm and leave it on for 4 hours.

[0216] (4)Test time point.

[0217] Before using the product (Day 0), 4 hours after using the product (Day 0 T 4h)

[0218] (5)Testing precautions.

[0219] (a) Before the test at each time point, the subject cleaned the test area inside the arm and then rested in a constant temperature and humidity room to ensure that the skin remained stable for 20 minutes before testing.

[0220] (b) During the trial, it is prohibited to use other products with the same dosage form and efficacy on the test area. Outdoor activities with strong sunlight should be reduced.

[0221] (6) Test the moisture content of the skin stratum corneum.

[0222] Testing instrument: Corneometer (skin moisture testing instrument).

[0223] Parameter description: The larger the measured value, the higher the moisture content of the skin's stratum corneum.

[0224] Test site: inner arm.

[0225] Test time points: D0, D0T4h.

[0226] Experimental results:

[0227] The test results of the stratum corneum moisture content test are shown in Tables 8 and 9. As shown in Tables 8 and 9, the 4-hour rate of change in stratum corneum moisture content of the skin care active is higher than the rate of change in stratum corneum moisture content of any single ingredient in the skin care active, indicating that the moisturizing effect of the skin care active is superior to that of any single ingredient in the skin care active. It should be noted that in the test of stratum corneum water content, the skin care products provided in the examples of the present application, ceramide NP, hydrolyzed sodium hyaluronate and sodium hyaluronate, peony root extract, and acetylglucosamine were respectively used as samples in the usage method and frequency of step (3), and the experiment was carried out in sequence; the amount of ceramide NP added was the same as the amount of ceramide NP added in the skin care active of the skin care product; the amount of peony root extract added was the same as the amount of peony root extract added in the skin care active of the skin care product; the amount of acetylglucosamine added was the same as the amount of acetylglucosamine added in the skin care active of the skin care product; the total amount of hydrolyzed sodium hyaluronate and sodium hyaluronate added was the same as the total amount of hydrolyzed sodium hyaluronate and sodium hyaluronate added in the skin care active of the skin care product.

[0228] Table 8 T0 stratum corneum water content test results

[0229] Table 9 T4 stratum corneum moisture content test results

[0230] Through tests at the cellular level, biochemical reagent level, skin model level, and human efficacy level, tests were conducted on cell proliferation rate, cell migration rate, DPPH clearance rate, ROS clearance rate, mitochondrial activity, TNF-ɑ, PGE-2, tissue morphology, FLG, and stratum corneum water content, respectively, verifying that the skin care actives provided in this application can effectively promote moisturizing, soothing, and repairing effects.

[0231] Experimental studies were conducted on the components and amounts of the skin care actives provided herein. The differences between the examples are as follows: the components and amounts of the skin care actives are shown in Table 10. The base used in each example is the same, specifically: 4 parts by weight of glycerin, 2 parts by weight of polydimethylsiloxane, 2 parts by weight of squalane, 0.6 parts by weight of acrylates, 1 part by weight of polysorbate 60, and the remaining parts by weight of deionized water, for a total of 100 parts by weight. In Examples 1-12, when the hyaluronic acid component is hydrolyzed sodium hyaluronate + sodium hyaluronate, the parts by weight represent the total parts of these two components, and the weight ratio of hydrolyzed sodium hyaluronate to sodium hyaluronate is always 3:2.

[0232] Table 10 Test parameters of various embodiments

[0233] As can be seen from Examples 1 to 12 above, the skincare actives provided in the present application have moisturizing, soothing, and repairing properties. The specific testing methods for the cell proliferation activity enhancement rates in each of the examples in Table 10 can be found in the descriptions of the above examples and are not detailed here. The testing methods for hyaluronidase inhibition activity and stratum corneum water content enhancement rates are as follows.

[0234] Experimental steps for hyaluronidase inhibition activity:

[0235] (1) Add 0.1 mL of CaCl solution (2.5 mol / L) to tubes A, B, C, and D, respectively.

[0236] (2) Add 0.5 mL of hyaluronidase solution (1250 U / mL) to tubes A and C.

[0237] (3) Replace the contents of tubes B and D with an equal amount of acetate buffer solution (pH = 5.6; a mixture of 0.2 mol / L sodium acetate and 0.2 mol / L acetic acid, 9.5:1) and keep them warm at 37°C for 20 min.

[0238] (4) Then add 0.5 mL of sample solution to tubes C and D, replace it with acetate buffer solution in tubes A and B, and keep it at 37°C for 20 min.

[0239] (5) Add 0.5 mL of sodium hyaluronate solution (0.5 mg / mL) to each tube, keep it at 37°C for 30 min, let it stand at room temperature for 5 min, and then place it in an 80°C water bath for 20 min.

[0240] (6) After taking out, add 0.1 mL of NaOH solution (0.4 mol / L) and 0.5 mL of acetylacetone solution to each tube, boil in water for 15 minutes, and then quickly ice-bathe for 5 minutes.

[0241] (7) Then add 1 mL of color developer and let it stand for 20 minutes for color reaction.

[0242] (8) The absorbance was measured at a wavelength of 547 nm, and the hyaluronidase inhibition rate was calculated according to the formula.

[0243] Experimental steps for stratum corneum water content:

[0244] 1. Experimental consumables.

[0245] (1) Delfin moisture meter.

[0246] (2) Any sample of Examples 1-15 provided in this application.

[0247] 2. Test site

[0248] Inside the arm, 3*3cm2 area.

[0249] 3. Test sample dosage

[0250] 2mg / cm2.

[0251] 4. Test steps

[0252] 1) For each implementation case, 5 people were selected. After determining the test area, a moisture meter was used to test the initial stratum corneum moisture content at T0, which was recorded as W0.

[0253] 2) After applying the sample, use a moisture meter to test the water content of the stratum corneum 30 minutes later, which is recorded as W1;

[0254] 3) The change rate of stratum corneum water content is: (W1-W0) / W0*%, and finally the average change rate of stratum corneum water content of 5 people is calculated.

[0255] The above description is only an implementation method of the present application and does not limit the patent scope of the present application. Any equivalent structure or equivalent process transformation made using the contents of the description and drawings of this application, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present application.

Claims

1. A skin care active ingredient, wherein, the skin care active ingredient comprises, by weight ratio, 0.1 - 15 parts by weight of a moisturizer and 0.05 - 2 parts by weight of a soothing and anti-allergic agent; wherein, the moisturizer comprises at least two of ceramide NP, sodium hyaluronate hydrolyzate, and sodium hyaluronate; the soothing and anti-allergic agent comprises peony root extract.

2. The skin care active substance according to claim 1, wherein, The skin care active ingredient comprises, by weight ratio: 0.5 - 5 parts by weight of ceramide NP, 0.1 - 10 parts by weight of sodium hyaluronate hydrolyzate and sodium hyaluronate; or, The skin care active ingredient comprises, by weight ratio: 0.5 - 5 parts by weight of ceramide NP, 0.1 - 10 parts by weight of sodium hyaluronate hydrolyzate; or, The skin care active ingredient comprises, by weight ratio: 0.5 - 5 parts by weight of ceramide NP, 0.1 - 10 parts by weight of sodium hyaluronate; or, The skin care active ingredient comprises, by weight ratio: 0.1 - 10 parts by weight of sodium hyaluronate hydrolyzate and sodium hyaluronate.

3. The skin care active substance according to claim 1 or 2, wherein, The skin care active ingredient further comprises 0.01 - 25 parts by weight of a moisturizing and repairing agent, and the moisturizing and repairing agent comprises at least one of N-acetylglucosamine, α-hydroxy acid, N-(2-hydroxyethyl)piperazine-N'-ethanesulfonic acid, phytic acid, and hexanoyl dipeptide-3-Nle acetate.

4. The skin care active substance according to claim 3, wherein, The skin care active ingredient comprises, by weight ratio: at least one of 0.01 - 5 parts by weight of N-acetylglucosamine, 0.01 - 5 parts by weight of α-hydroxy acid, 0.01 - 5 parts by weight of N-(2-hydroxyethyl)piperazine-N'-ethanesulfonic acid, 0.01 - 5 parts by weight of phytic acid, and 0.01 - 5 parts by weight of hexanoyl dipeptide-3-Nle acetate.

5. The skin care active substance according to claim 1, wherein, The skin care active ingredient consists of components in the following weight ratio: 0.5 - 5 parts by weight of ceramide NP, 0.1 - 10 parts by weight of sodium hyaluronate hydrolyzate and sodium hyaluronate, 0.05 - 2 parts by weight of peony root extract, 0.01 - 5 parts by weight of N-acetylglucosamine; or, The skin care active ingredient consists of components in the following weight ratio: 0.5 - 5 parts by weight of ceramide NP, 0.1 - 10 parts by weight of sodium hyaluronate hydrolyzate and sodium hyaluronate, 0.05 - 2 parts by weight of peony root extract; or, The skin care active ingredient consists of components in the following weight ratio: 0.5 - 5 parts by weight of ceramide NP, 0.1 - 10 parts by weight of sodium hyaluronate hydrolyzate, 0.05 - 2 parts by weight of peony root extract; or, The skin care active ingredient consists of components in the following weight ratio: 0.5 - 5 parts by weight of ceramide NP, 0.1 - 10 parts by weight of sodium hyaluronate, 0.05 - 2 parts by weight of peony root extract; or, The skin care active ingredient consists of components in the following weight ratio: 0.1 - 10 parts by weight of sodium hyaluronate hydrolyzate and sodium hyaluronate, 0.05 - 2 parts by weight of peony root extract, 0.01 - 5 parts by weight of N-acetylglucosamine.

6. The skin care active substance according to claim 2 or 5, wherein, Among the 0.1 - 10 parts by weight of sodium hyaluronate hydrolyzate and sodium hyaluronate, the weight ratio of sodium hyaluronate hydrolyzate to sodium hyaluronate is (2.5 - 4):(1.5 - 3).

7. A skin care product, wherein, Comprising the skin care active ingredient according to any one of claims 1 to 6.

8. The skin care product according to claim 7, wherein, The skin care product comprises 0.15 - 42 parts by weight of the skin care active ingredient and 7.5 - 14 parts by weight of the base material according to the weight ratio.

9. The skin care product according to claim 8, wherein, The skin care product is composed of the skin care active ingredient, the base material and deionized water.

10. The skin care product according to claim 8 or 9, wherein, The base material is composed of components with the following weight ratio: 3 - 5 parts by weight of glycerol, 2 - 3 parts by weight of polydimethylsiloxane, 1 - 3 parts by weight of squalane, 0.5 - 1 part by weight of acrylic acid or acrylate or C10 - 30 alkanol acrylate cross-linked polymer, 1 - 2 parts by weight of polysorbate - 60.

Images